Dr Luo also co-founded and served as Chairman of the board of Avida Biomed, an NGS-based liquid biopsy technology company that was acquired by Agilent in 2022. Dr Luo is a Venture Partner of Illumina Ventures. Steve brings to Alamar over 20 years of experience in technology innovation and management in biotech and high-tech industries. Prior to ACD, Steve co-founded Genospectra, served as its CTO and led the development of its microarray instrumentation systems. Xiao-Jun is a successful R&D leader with more than 20 years of experience in the life sciences and molecular diagnostics industries. Yiyuan brings to Alamar over 10 years of experience in antibody discovery and engineering. Berdine is a seasoned veteran of the life science industry and has over 20 years’ experience in biotech strategy development, product management, and marketing. Berdine has a successful track record of commercializing innovative technologies and extensive experience building while leading commercial organizations to support rapid growth.
Hayward, United States
Founded in 2018
11-50 Employees
Working industry
Biotechnology
Type of company
Manufacturer, Service provider
Ownership structure
Privately Held
Locations
1 Headquarter
Number of products
15 Products
Specialised areas
Biotechnology, Health Care, Medical
Alamar Biosciences offers a wide range of products and services
Product
NULISAseq | Comprehensive Inflammation Panel
Go to product >
Product
NULISA™ Custom Assay Solutions for your research needs
Go to product >
Product
Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform - Alamar Biosciences
Go to product >
Product
Alamar’s Technology Access Program for Researchers
Go to product >
Product
ARGO™ System | Precision Proteomics at the Push of a Button
Go to product >
Product
NULISA: a novel proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing - Alamar Biosciences
Go to product >
Product
Discover Partnership Opportunities with Alamar Biosciences, Inc.
Go to product >
Product
Alamar Biosciences Unveils Novel Proteomics Platform
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Alamar Biosciences operates in 1 country around the world
Get an overview of the locations of Alamar Biosciences
Location
Country
State
City
Headquarter
United States
California
Hayward
Some frequent questions that have been asked about Alamar Biosciences
Where is Alamar Biosciences located?
The company headquarter of Alamar Biosciences is located in Hayward, California, United States. It's worth noting, that the company may have more locations
How many employees does Alamar Biosciences approximately have?
As of the latest available information Alamar Biosciences has around 11-50 employees worldwide.
When was Alamar Biosciences founded?
Alamar Biosciences was founded in 2018
In which industries does Alamar Biosciences mainly work?
The company Alamar Biosciences has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Alamar Biosciences
REALM IDx Inc.
Aliso Viejo, United States
1001-5000 Employees
2021
We believe today’s innovations in integrated diagnostics will become tomorrow’s standard of care throughout the healthcare continuum. At REALM, it is our mission to continuously seek the answers within to improve quality of life for all. Fujii’s extensive business career ranges from medical services, information technology, and consumer products to investment banking. From 1986 to 1993, Fujii held the role as the first Japanese M&A investment banker in New York with Credit Suisse First Boston and Goldman Sachs. George has over 30 years of experience in creating value in the life science and high technology industries. Michelle also serves as the General Counsel and Secretary of Ambry Genetics. Chen served as the Chief Financial Officer of Thermo Fisher Scientific’s Transplant Diagnostics Business from November 2017 to September 2021. Chen served as the VP of M&A/Business Development at Response Genetics.
Alveo Technologies
San Francisco, United States
51-100 Employees
2014
With more than 20 years of experience in strategic business development for medical device and diagnostic companies ranging from start-ups to mature global corporations, Erik most recently served as Vice President of Business Development at Atonarp, Inc., and previously as Head of Business Development for Thermo Fisher Scientific, and previously as Senior Vice President of Business Development and Product Management at Mesa Biotech prior to its acquisition by Thermo Fisher. Slava Elagin brings to Alveo more than 20 years of experience in the in vitro diagnostics and medical devices industry. Food & Drug Administration clearances and commercialization and is the author on 12 U.S. John, a seasoned Manufacturing Operations Leader, spans small startups to industry giants like Flextronics, Mars Petcare, and Tesla Motors, showcasing expertise in management, manufacturing, and logistics. Kevin Gunning oversees Alveo’s Quality Management System and holds more than 25 years of experience working in the medical device, pharmaceutical, biotechnology and clinical laboratory industries. Mary McFillin is a senior global product marketing manager with extensive experience in the point-of-care diagnostics industry, leading strategy, development and support of in vitro diagnostics medical devices throughout the product life cycle. As a senior product management executive, Mary leads Alveo’s strategic marketing and target market development. Matthew Marsh has nearly 25 years of experience driving growth and value creation for customers, employees and shareholders.
Acuamark Diagnostics
New York, United States
1-10 Employees
2012
At AcuamarkDX, we are shaping a new future in cancer diagnostics and making early cancer detection a standard of primary care. AcuamarkDx is pleased to be featured as a diagnostics company on the rise in the premiere issue of ENMEDIA magazine. Cochrane is the Chair of UNC’s Board of Trustees. Director R&D, Applied Biosystems Inc.; SVP Product Development & CTO, Helicos BioSciences Corp.; SVP R&D, Affymetrix; Independent Consultant. Director, Clinical Affairs and Regulatory Submissions at Abbott Molecular Diagnostics, at Baxter as Director of Clinical Affairs, at Oncor and at Boehringer Mannheim. Flom has led for over 30 products through regulatory filings and registration in the US and numerous international product registrations. Howard is a senior entrepreneurial executive with thirty-years of experience in operations, finance, business development, and investor relations at biotechnology companies. Founded UniTaq Bio to commercialize novel methods for highly multiplexed qPCR for diagnostics.
DiamiR
South Brunswick, United States
1-10 Employees
1998
Our mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for early detection and monitoring of brain and synaptic health conditions, including mild cognitive impairment and Alzheimer’s disease, to enable earlier intervention and better planning of care. Mireskandari has over 12 years of life sciences industry experience with a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Kumar is an accomplished research & development leader, with experience in leading CLIA facility operations. Kumar has 20+ years of experience in the development of technologies for molecular diagnostic and other applications. Kenny Ablordeppey serves as the Laboratory Supervisor and Project Manager at DiamiR. Rinder is a volunteer for the ASCP, serving on committees tasked with education and professional development, and currently is President of the ASCP, serving the pathology and laboratory professional workforce. Robert Rissman, PhD, is a Professor of Neurosciences at the University of California San Diego (UCSD), a Research Biologist at VA San Diego, Founding Director of UCSD’s Alzheimer's Disease Cooperative Study (ADCS) Biomarker Core, as well as, Founding Director of the Biomarker Core for University of Southern California (USC) Alzheimer’s Therapeutic Research Institute (ATRI) in San Diego. Mikhail Denissenko has over 20 years of experience in Diagnostics and Drug Discovery.
Crystal Genetics, Inc.
California, United States
1-10 Employees
2016
Kermani is the Founder and CEO of Crystal Genetics, Inc. Mark Baudler is a partner at Wilson Sonsini Goodrich & Rosati (WSGR). Mark Sutherland is the Founder and Principal of Sutherland Life Sciences LLC, a consulting firm which provides business consulting services to a wide variety of Life Sciences, Genomics, Molecular Diagnostics, Immuno-Oncology and Biotechnology companies. Arnold Oliphant is the CTO of Omniome, and is responsible for leading the research and development of Omniome’s sequencing technology. Yeung founded Triware Networld Capital, a Venture Capital and Investment firm. Pirooz Parvarandeh is the Chief Operating Officer at Aquantia (NYSE: AQ). Kamran Tahamtanzadeh (President & Chief Executive Officer of Inanovate Inc a leading proteomics company developing the world’s first multimodal-multiplexing protein measurement platform for disease diagnostics applications, former CEO of EpiCELONA, LLC and Founding CEO at PrognosDx Health, Inc a pioneering Cancer Epigenetics company), is an internationally recognized business executive with focus on Life Sciences, Molecular Diagnostics, Clinical Diagnostics and Medical Oncology market segments. Cancer screening is the first line-of-defense in detecting this disease early, and consequently changing its outcomes, dramatically.
Alithea Genomics
Lausanne, Switzerland
1-10 Employees
2020
All our products are linked by a common mission: to enable simple, fast and cost-efficient generation of "big RNA data" from diverse sample types. Daniel is the CTO and co-founder of Alithea since its incorporation in May 2020. Riccardo is the CEO and co-founder of Alithea Genomics since its incorporation in May 2020. Jan co-founded and served as director of Genohm, which was acquired by Agilent Technologies in 2018. Jan also served as Director and Chairman of Oystershell laboratories, a world-class developer of innovative consumer healthcare products. Roger is founder and CEO of Holonautic, a leader in the VR application development space. Since 2013, Deplancke is a group leader at the Swiss Institute of Bioinformatics. In 2011, Deplancke co-founded Genohm, a company delivering software (big data management) products and services for pharmaceutical and R&D laboratories, which was acquired by Agilent in May 2018.